Navigation Links
Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
Date:9/22/2011

SAN DIEGO, Sept. 22, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that management will be presenting at the JMP Securities Healthcare Conference in New York. The presentation is scheduled for Wednesday, September 28 at 8:30 a.m. EDT (5:30 a.m. PDT). To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the company's Web site at www.halozyme.com. A replay will be available for 90 days after the event.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the insulin, cancer, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze(TM) technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche, Baxter, ViroPharma and Intrexon to apply Enhanze technology to therapeutic biologics including Herceptin®, MabThera®, immunoglobulin, Cinryze® and recombinant human alpha 1-antitrypsin. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant un
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
2. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
3. Halozyme Therapeutics to Present at Upcoming Investor Conferences
4. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
5. Halozyme Therapeutics to Host Research Day for Investors and Analysts
6. Halozyme Therapeutics to Present at Upcoming Investor Conferences
7. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
8. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
9. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
10. Halozyme Receives $5.5 Million Payment From Baxter
11. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... 12, 2014 The DNA Microarray ... 2013, and is expected to grow at a ... Browse through the TOC of the DNA Microarray ... and segments, with help of various tables and ... DNA Microarray market consists of instrument, consumables, and ...
(Date:12/13/2014)... (PRWEB) December 13, 2014 QuickSTAT is ... network and Cold Chain capabilities, and is delighted to ... Paris, France, to serve Life Science clients in the ... with a controlled-ambient warehouse, will provide 24/7 transportation and ... and investigational drugs, patient-clinical specimens, API, following IATA rules ...
(Date:12/13/2014)... RARITAN, N.J. and SAN ANTONIO ... Development, LLC (Janssen) today announced the presentation of data ... the Phase 3 EPO-ANE-3010 study evaluating epoetin alfa plus ... treat anemia in patients with metastatic breast cancer receiving ... primary objective, which was to rule out a 15 ...
(Date:12/12/2014)... Electronic Data Interchange (EDI) has helped evolve ... chain management to depend from paper based to ... with the use of EDI such as cost ... improve the acceptance of this technology in the ... and 107 figures spread through 210 pages and ...
Breaking Biology Technology:DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 2DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 3DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 4Quick Opens Office in France to Serve Life Science Community In France and Neighboring French-Speaking Countries 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 4Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 5Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 6Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 7Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 8Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 9Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 10Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 11Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 12The Global EDIS Market Was Valued at $312.00 Million in 2014 - New Report by MarketsandMarkets 2The Global EDIS Market Was Valued at $312.00 Million in 2014 - New Report by MarketsandMarkets 3The Global EDIS Market Was Valued at $312.00 Million in 2014 - New Report by MarketsandMarkets 4
... division of Nycomed,US Inc., today announced the FDA ... formulation compares to Taro,s Referenced Listed Drug (RLD),and ... # 0168-0133-15), 30g tubes,(NDC # 0168-0133-30) and 45g ... Clotrimazole Cream is another illustration of,Fougera,s robust product ...
... HAYWARD, Calif., Sept. 12 Acologix, Inc., a ... two,preclinical studies demonstrating that AC-100, its therapeutic product,candidate ... bone and,dental cells, promotes cartilage regeneration in large ... Catherine A. Middleton-Hardie on September,13, 2008 at the ...
... -- Simcere Pharmaceutical,Group (NYSE: SCR ), a ... manufacturer of the patented anti-cancer biotech,product Endu in ... Zhou,and Mr. Xiaojin Yin to Executive Vice President ... Mr. Qingsen Li to the newly created,position of ...
Cached Biology Technology:Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the 30th ASBMR Annual Meeting 2Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the 30th ASBMR Annual Meeting 3Simcere Pharmaceutical Group Announces Two Senior Promotions and Appointment of New Vice President of Human Resources 2
(Date:11/21/2014)... YORK , Nov. 19, 2014  Earlier this ... at New York College, and one of the most ... biosensor signals that are transmitted from Smartphones to third ... were Smartphones and has one of the earliest known ... discussing its usage in the military, child care, elder ...
(Date:11/18/2014)... BOSTON , Nov. 17, 2014   ... HealthCare and EMC collaborate to develop The Partners ... , The Partners Data Lake will allow ... to improve diagnostics, treatment and the lives of ... support research and clinical activities across the Partners ...
(Date:11/11/2014)...  Forensicon, Inc., a Chicago -based ... the promotion of Yaniv Schiff from Senior ... Schiff,s new role as Director, he will lead company ... examiners and provide leadership within the company,s digital forensics ... Schiff joined Forensicon in 2006 ...
Breaking Biology News(10 mins):Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
... hiding in the human immune system. Accessing it, however, ... roles that the immune system plays can mask the ... issues. Now, research led by scientists from the California ... generation of microchips developed by the team can quickly ...
... find happy guys significantly less sexually attractive than swaggering or ... study that helps to explain the enduring allure of "bad ... which may cause men to smile less on dates, and ... dramatic gender differences in how men and women rank the ...
... Ariz. The International Institute for Species Exploration at ... around the world scientists responsible for species exploration ... 10 new species described in 2010. The May 23 ... Carolus Linnaeus, the Swedish botanist who was responsible for ...
Cached Biology News:Improving health assessments with a single cell 2Improving health assessments with a single cell 3Happy guys finish last, says new study on sexual attractiveness 2Happy guys finish last, says new study on sexual attractiveness 3Scientists list top 10 new species 2Scientists list top 10 new species 3Scientists list top 10 new species 4Scientists list top 10 new species 5Scientists list top 10 new species 6Scientists list top 10 new species 7
... Agencourt AMPure is a magnetic ... requires no sample transfer, centrifugation ... purifies small and large PCR ... 384-well microplates. Agencourt AMPure can ...
... Agencourt AMPure is a ... that requires no sample transfer, ... efficiently purifies small and large ... or 384-well microplates. Agencourt AMPure ...
... designed for the fast and simple integration ... any position (for the generation of transgenic ... designed to allow neomycin / kanamycin selection ... a prokaryotic promoter (gb2) for expression of ...
Includes a choice of any 3 EasySep mouse selection kits and EasySep magnet...
Biology Products: